
Aldoxorubicin for metastatic, locally advanced or unresectable soft tissue sarcoma – second line
NIHR HSRIC

Record Status

This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

NIHR HSRIC. Aldoxorubicin for metastatic, locally advanced or unresectable soft tissue sarcoma – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016

Authors' conclusions

Soft tissue sarcomas are a group of rare cancers that affect tissues that connect, support and surround other body structures and organs. Soft tissue sarcoma can affect any part of the body including the arms, legs and torso. Soft tissue sarcoma can develop in fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Aldoxorubicin is a new chemotherapy drug given in a drip directly into a vein. Aldoxorubicin is changed into the existing chemotherapy drug doxorubicin inside tumours, and may be useful in treating soft tissue sarcoma where previous treatment has failed. If licensed for use in the UK, aldoxorubicin will be a new treatment for people with soft tissue sarcoma.

Final publication URL

<http://www.hsrhc.nihr.ac.uk/topics/aldoxorubicin-for-metastatic-locally-advanced-or-unresectable-soft-tissue-sarcoma-second-line/>

Indexing Status

Subject indexing assigned by CRD

MeSH

Humans; Doxorubicin; Hydrazones; Sarcoma

Language Published

English

Country of organisation

England

English summary

An English language summary is available.

Address for correspondence

NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber

32016000825

Date abstract record published

22/06/2016